Physician profile
Harry David Stone
NPI 1942367388
$7,296.51
in general payments reported to CMS, 2019-2025
24 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $694 · 2021: $773 · 2022: $1,085 · 2023: $1,666 · 2024: $1,171 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,990 · Education: $64.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,989.72 |
| Education | $64.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $2,649.82 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Pfizer INC. | $695.08 | 2019-2025 | |
| Genzyme Corporation | $545.13 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $452.29 | 2019-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $399.49 | 2019-2024 | Tezspire, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $384.00 | 2019-2025 | |
| Grifols USA, LLC | $357.46 | 2019-2025 | Xembify |
| Glaxosmithkline, LLC. | $273.17 | 2020-2025 | Nucala |
| Octapharma USA, INC. | $231.01 | 2023 | Cutaquig |
| Optinose US, INC. | $220.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.47 | 2021-2025 | Cuvitru, Takhzyro |
| Pharming Healthcare, INC. | $176.96 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $102.83 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.38 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $88.32 | 2021-2023 | Orladeyo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $84.50 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $84.50 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $64.14 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $47.15 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $41.32 | 2025 | Xhance, Nuzyra |
| Teva Pharmaceuticals USA, INC. | $40.99 | 2021-2022 | |
| Amgen INC. | $29.10 | 2024 | Actimmune |
| Biocryst Pharmaceuticals, INC. | $17.85 | 2020 | |
| Jubilant Hollisterstier LLC | $17.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.